Hospital
Baptist Healthcare System, INC
Baptist Healthcare System, INC was paid $72.57M by Medicaid between Jan 2018 and Dec 2024, across 426 billing codes. Its largest line is 99283, emergency room visit (moderate) — 10% of everything it billed.
33Billing provider infoBAPTIST HEALTHCARE SYSTEM, INC
PADUCAH, KY 42003
PADUCAH, KY 42003
33aNPI1730264128assigned 10/26/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$72.57M
24GClaims1,523,785
24DCodes billed426
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Kentucky
Rank by total paid#10 of 36
Median peer was paid$36.08M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CARRICO, RICHARD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 205,981 | $9.42M | |
| 2019 | 198,652 | $9.74M | |
| 2020 | 184,775 | $8.13M | |
| 2021 | 238,412 | $10.76M | |
| 2022 | 244,979 | $11.47M | |
| 2023 | 247,883 | $12.53M | |
| 2024incomplete | 203,103 | $10.52M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 50,039 | 42,781 | $7.42M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.7% | 25,100 | 20,650 | $5.57M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.5% | 11,324 | 9,840 | $3.99M |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 4.2% | 1,585 | 1,174 | $3.07M |
| 41899 | Unlisted procedure, dentoalveolar structures | 3.8% | 2,476 | 2,317 | $2.77M |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 3.1% | 8,551 | 7,940 | $2.26M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.8% | 7,064 | 5,477 | $2.01M |
| G0378 | Hospital observation service, per hour | 2.2% | 5,785 | 4,507 | $1.63M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 9,361 | 7,812 | $1.58M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.0% | 3,943 | 3,332 | $1.42M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.6% | 12,274 | 7,901 | $1.13M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.6% | 9,716 | 3,206 | $1.13M |
414 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.4% | 3,317 | $996K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 14,468 | $912K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.2% | 2,792 | $867K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 1.2% | 1,824 | $861K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.2% | 3,986 | $860K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.1% | 26,621 | $824K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 27,510 | $779K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.0% | 20,078 | $760K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.0% | 7,614 | $754K |
| 80053 | Comprehensive metabolic panel | 1.0% | 77,927 | $739K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,502 | $719K |
| 93017 | <1% | 2,970 | $688K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 32,149 | $675K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,644 | $647K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,445 | $611K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 698 | $538K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,406 | $530K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,351 | $501K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 7,967 | $498K |
| 71045 | Radiologic examination, chest; single view | <1% | 19,308 | $496K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 13,364 | $488K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 1,107 | $462K |
| 36415 | Collection of venous blood by venipuncture | <1% | 133,071 | $462K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 69,954 | $457K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,120 | $455K |
| 96367 | <1% | 5,080 | $452K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 14,975 | $434K |
| 74018 | <1% | 6,646 | $410K | |
| 93350 | <1% | 1,480 | $405K | |
| 72131 | <1% | 2,228 | $399K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,497 | $388K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 4,523 | $382K |
| 72141 | <1% | 1,569 | $372K | |
| 73630 | <1% | 4,439 | $365K | |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 415 | $362K |
| 72110 | <1% | 2,964 | $358K | |
| 93971 | <1% | 2,280 | $353K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 9,783 | $324K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 8,536 | $321K |
| 70486 | <1% | 1,730 | $318K | |
| 95886 | <1% | 1,223 | $310K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 3,335 | $309K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,037 | $297K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 8,870 | $296K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 867 | $289K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,548 | $283K |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 2,699 | $279K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,407 | $275K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 9,438 | $272K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,083 | $256K |
| 71250 | <1% | 2,227 | $251K | |
| 87481 | <1% | 7,503 | $249K | |
| 96376 | <1% | 5,919 | $246K | |
| 77336 | <1% | 2,915 | $242K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,947 | $239K |
| 73610 | <1% | 3,124 | $238K | |
| 93880 | <1% | 2,091 | $236K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 8,167 | $225K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,440 | $221K |
| 76775 | <1% | 1,673 | $220K | |
| 97597 | <1% | 1,751 | $217K | |
| 73030 | <1% | 3,205 | $217K | |
| 73562 | <1% | 2,772 | $211K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,660 | $209K |
| 73130 | <1% | 2,801 | $202K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 23,203 | $198K |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 2,180 | $194K |
| 80050 | General health panel | <1% | 5,349 | $184K |
| 87507 | <1% | 619 | $181K | |
| 84484 | <1% | 18,879 | $179K | |
| 72082 | <1% | 656 | $179K | |
| 93970 | <1% | 891 | $173K | |
| 83880 | <1% | 5,784 | $172K | |
| C1769 | Guide wire | <1% | 1,402 | $169K |
| 73110 | <1% | 2,223 | $166K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 20,021 | $163K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,055 | $157K |
| 80061 | Lipid panel | <1% | 13,218 | $157K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,661 | $154K |
| 77300 | <1% | 760 | $146K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 2,858 | $142K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 7,735 | $136K |
| 72100 | <1% | 1,891 | $135K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,700 | $132K |
| 87512 | <1% | 3,445 | $123K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,086 | $123K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 4,261 | $119K |
| 72040 | <1% | 1,375 | $116K | |
| 0100U | <1% | 560 | $114K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,224 | $110K |
| 88304 | <1% | 3,216 | $107K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 14,194 | $104K |
| 74178 | <1% | 200 | $103K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 14,379 | $103K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,334 | $101K |
| 72114 | <1% | 717 | $100K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 368 | $98K |
| 76536 | <1% | 1,172 | $96K | |
| 77412 | <1% | 458 | $95K | |
| 95816 | <1% | 362 | $94K | |
| 95911 | <1% | 232 | $93K | |
| 73502 | <1% | 1,822 | $92K | |
| 83690 | <1% | 16,934 | $92K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,792 | $92K |
| 72050 | <1% | 918 | $92K | |
| 76642 | <1% | 1,076 | $91K | |
| 83605 | <1% | 10,772 | $90K | |
| 72128 | <1% | 556 | $88K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 11,092 | $87K |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 5,463 | $83K |
| 81025 | <1% | 15,132 | $82K | |
| 87081 | <1% | 10,995 | $79K | |
| 88307 | <1% | 1,281 | $78K | |
| 84145 | <1% | 3,874 | $74K | |
| 87040 | <1% | 9,317 | $73K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 290 | $73K |
| J2704 | Injection, propofol, 10 mg | <1% | 20,051 | $71K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 94 | $71K |
| 80306 | <1% | 5,412 | $70K | |
| 72072 | <1% | 813 | $69K | |
| 0097U | <1% | 331 | $68K | |
| 70491 | <1% | 290 | $68K | |
| 73590 | <1% | 1,102 | $67K | |
| 81001 | <1% | 24,040 | $66K | |
| 80074 | <1% | 1,475 | $66K | |
| 85027 | <1% | 11,236 | $64K | |
| 83735 | <1% | 10,230 | $59K | |
| 82607 | <1% | 4,352 | $57K | |
| 93923 | <1% | 732 | $56K | |
| 87563 | <1% | 2,077 | $55K | |
| 85379 | <1% | 6,704 | $55K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,092 | $54K |
| 94060 | <1% | 593 | $53K | |
| 82728 | <1% | 4,510 | $52K | |
| J3490 | Unclassified drugs | <1% | 627 | $51K |
| 73090 | <1% | 731 | $51K | |
| 71271 | <1% | 1,021 | $50K | |
| 84439 | <1% | 5,907 | $47K | |
| 84702 | <1% | 3,659 | $47K | |
| 86850 | <1% | 5,415 | $46K | |
| 85730 | <1% | 8,773 | $45K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,924 | $45K |
| 85610 | <1% | 13,536 | $44K | |
| 87186 | <1% | 5,293 | $39K | |
| 84466 | <1% | 3,749 | $39K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,297 | $38K |
| 93975 | <1% | 200 | $38K | |
| 82803 | <1% | 2,081 | $37K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,804 | $37K |
| 77080 | <1% | 957 | $37K | |
| 87070 | <1% | 5,984 | $36K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 531 | $36K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 934 | $36K |
| 58661 | <1% | 29 | $35K | |
| 84703 | <1% | 5,591 | $34K | |
| 90715 | <1% | 1,405 | $34K | |
| 47562 | <1% | 27 | $32K | |
| 74022 | <1% | 295 | $31K | |
| 81003 | <1% | 14,943 | $31K | |
| 94726 | <1% | 900 | $30K | |
| 82077 | <1% | 2,688 | $30K | |
| 77066 | Tomosynthesis, mammo | <1% | 393 | $29K |
| 73080 | <1% | 491 | $29K | |
| 82746 | <1% | 2,209 | $28K | |
| 82962 | <1% | 8,524 | $28K | |
| 36600 | <1% | 1,936 | $28K | |
| 59025 | Fetal non-stress test | <1% | 316 | $28K |
| 83540 | <1% | 4,921 | $27K | |
| 77334 | <1% | 61 | $27K | |
| 86140 | <1% | 6,686 | $26K | |
| 86803 | <1% | 2,137 | $25K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,701 | $24K |
| 70496 | <1% | 98 | $24K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 14,708 | $24K |
| 73560 | <1% | 306 | $24K | |
| 87077 | <1% | 3,035 | $22K | |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 1,698 | $22K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 125 | $22K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 285 | $22K |
| 82150 | <1% | 3,815 | $21K | |
| 70498 | <1% | 118 | $21K | |
| 86900 | <1% | 5,642 | $21K | |
| 86901 | <1% | 5,614 | $21K | |
| 87147 | <1% | 3,010 | $20K | |
| 74019 | <1% | 339 | $20K | |
| 95909 | <1% | 100 | $20K | |
| 76942 | <1% | 325 | $20K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 30,365 | $20K |
| 87807 | <1% | 1,395 | $19K | |
| 76830 | Ultrasound, transvaginal | <1% | 244 | $17K |
| 97161 | <1% | 423 | $17K | |
| 87634 | <1% | 230 | $17K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 42 | $17K |
| 78226 | <1% | 67 | $17K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,299 | $17K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 20,737 | $17K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 274 | $17K |
| 84146 | <1% | 867 | $16K | |
| 93246 | <1% | 466 | $16K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,600 | $16K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 51 | $16K |
| 82550 | <1% | 2,595 | $15K | |
| 76870 | <1% | 210 | $15K | |
| 72052 | <1% | 93 | $15K | |
| 80143 | <1% | 906 | $15K | |
| 87529 | <1% | 210 | $15K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 58 | $14K |
| 84481 | <1% | 963 | $14K | |
| 94729 | <1% | 455 | $14K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 8,323 | $14K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,309 | $14K |
| 84403 | <1% | 681 | $13K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,179 | $13K |
| 0012A | <1% | 687 | $13K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 836 | $13K |
| 73140 | <1% | 195 | $12K | |
| 87205 | <1% | 3,332 | $12K | |
| 82948 | <1% | 2,718 | $12K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 66 | $12K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 165 | $11K |
| 77065 | Tomosynthesis, mammo | <1% | 207 | $11K |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 2,359 | $11K |
| 0011A | <1% | 795 | $11K | |
| 80179 | <1% | 835 | $11K | |
| 86038 | <1% | 906 | $10K | |
| 12001 | <1% | 115 | $10K | |
| 94760 | <1% | 1,369 | $10K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,253 | $10K |
| 71101 | <1% | 118 | $10K | |
| 93356 | <1% | 474 | $10K | |
| 87210 | <1% | 2,264 | $10K | |
| 87522 | Neg quan hep c or qual rna | <1% | 279 | $9K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,051 | $9K |
| 93225 | <1% | 124 | $9K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 39 | $9K |
| 93226 | <1% | 71 | $9K | |
| 84112 | <1% | 96 | $8K | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 2,102 | $8K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 6,367 | $8K |
| 83615 | <1% | 1,475 | $8K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 111 | $7K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,206 | $7K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,204 | $7K |
| 85652 | <1% | 3,087 | $7K | |
| 97162 | <1% | 193 | $7K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 84 | $7K |
| 86665 | <1% | 193 | $7K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,540 | $7K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 51 | $7K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,315 | $7K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 473 | $7K |
| 73221 | <1% | 30 | $7K | |
| 87088 | <1% | 949 | $7K | |
| 83550 | <1% | 738 | $6K | |
| 70360 | <1% | 71 | $6K | |
| 78227 | <1% | 23 | $6K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,185 | $6K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 26 | $6K |
| 99152 | <1% | 149 | $6K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 76 | $6K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,330 | $5K |
| 85651 | <1% | 1,524 | $5K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,042 | $5K |
| 38222 | <1% | 15 | $5K | |
| 82043 | <1% | 1,092 | $5K | |
| 88112 | <1% | 120 | $5K | |
| 94664 | <1% | 243 | $5K | |
| 87150 | <1% | 26 | $5K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,149 | $5K |
| C1726 | Catheter, balloon dilatation, non-vascular | <1% | 17 | $5K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 20 | $5K |
| 84100 | <1% | 1,053 | $5K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,707 | $5K |
| 82570 | <1% | 1,017 | $5K | |
| 96368 | <1% | 36 | $5K | |
| 96417 | <1% | 49 | $4K | |
| 75574 | <1% | 13 | $4K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 2,404 | $4K |
| 64447 | <1% | 30 | $4K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,711 | $4K |
| 43235 | <1% | 19 | $4K | |
| 77290 | <1% | 23 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,727 | $4K |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 60 | $4K |
| 73552 | <1% | 56 | $4K | |
| 86003 | <1% | 33 | $4K | |
| 73060 | <1% | 61 | $3K | |
| 84550 | <1% | 908 | $3K | |
| 93325 | <1% | 46 | $3K | |
| 77012 | <1% | 15 | $3K | |
| 82731 | <1% | 50 | $3K | |
| 86664 | <1% | 169 | $3K | |
| 10060 | <1% | 13 | $3K | |
| 86308 | <1% | 637 | $3K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 25 | $3K |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 975 | $3K |
| 82378 | <1% | 199 | $3K | |
| 84207 | <1% | 126 | $3K | |
| 95812 | <1% | 12 | $3K | |
| A9573 | Injection, gadopiclenol, 1 ml | <1% | 61 | $3K |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 58 | $3K |
| 82805 | <1% | 56 | $3K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,128 | $3K |
| 88300 | <1% | 139 | $3K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,843 | $3K |
| 87075 | <1% | 314 | $2K | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 1,530 | $2K |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 393 | $2K |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 664 | $2K |
| 86592 | <1% | 504 | $2K | |
| 82248 | <1% | 426 | $2K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 35 | $2K |
| 74230 | <1% | 34 | $2K | |
| 76801 | <1% | 25 | $2K | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 13 | $2K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 81 | $2K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 184 | $2K |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 287 | $2K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 103 | $2K |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 406 | $2K |
| 82247 | <1% | 317 | $2K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 209 | $2K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,193 | $2K |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 31 | $2K |
| 88302 | <1% | 78 | $2K | |
| 83874 | <1% | 131 | $2K | |
| 86431 | <1% | 291 | $2K | |
| 86663 | <1% | 108 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 487 | $2K |
| 87185 | <1% | 340 | $1K | |
| 97032 | <1% | 90 | $1K | |
| 87176 | <1% | 278 | $1K | |
| 82784 | <1% | 141 | $1K | |
| A4648 | Tissue marker, implantable, any type, each | <1% | 13 | $1K |
| 72120 | <1% | 17 | $1K | |
| 72070 | <1% | 15 | $1K | |
| 87493 | <1% | 51 | $1K | |
| 87625 | <1% | 71 | $1K | |
| 83516 | <1% | 87 | $1K | |
| 76981 | <1% | 16 | $995.00 | |
| 88142 | <1% | 43 | $927.19 | |
| 84156 | <1% | 248 | $919.45 | |
| 88311 | <1% | 87 | $918.37 | |
| 86780 | <1% | 85 | $900.25 | |
| 97803 | <1% | 167 | $869.03 | |
| 84630 | <1% | 103 | $868.26 | |
| 92610 | <1% | 13 | $792.64 | |
| 84425 | <1% | 50 | $790.02 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 93 | $778.84 |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 322 | $778.71 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 15 | $778.36 |
| 77417 | <1% | 34 | $765.74 | |
| 82553 | <1% | 81 | $695.35 | |
| 82525 | <1% | 66 | $672.77 | |
| 97802 | <1% | 202 | $630.31 | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 23 | $622.44 |
| 86376 | <1% | 55 | $614.82 | |
| 88313 | <1% | 27 | $550.46 | |
| 36416 | <1% | 236 | $525.66 | |
| 87899 | <1% | 100 | $512.99 | |
| 93242 | <1% | 12 | $496.10 | |
| 82140 | <1% | 44 | $488.72 | |
| 82565 | <1% | 39 | $461.36 | |
| 82270 | <1% | 114 | $456.85 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 285 | $442.27 |
| 82375 | <1% | 31 | $431.68 | |
| 83001 | <1% | 28 | $424.55 | |
| 83002 | <1% | 28 | $423.18 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 93 | $368.27 |
| 86706 | <1% | 46 | $368.22 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 169 | $366.85 |
| 82670 | <1% | 16 | $363.78 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 313 | $350.49 |
| 88342 | <1% | 15 | $345.51 | |
| 84402 | <1% | 16 | $337.79 | |
| 86618 | <1% | 13 | $332.91 | |
| 94761 | <1% | 52 | $330.62 | |
| 84446 | <1% | 33 | $328.51 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 48 | $292.60 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 423 | $278.21 |
| 82009 | <1% | 69 | $269.46 | |
| 84590 | <1% | 33 | $268.54 | |
| 99406 | <1% | 45 | $233.69 | |
| 84144 | <1% | 13 | $229.88 | |
| 87340 | <1% | 25 | $229.41 | |
| 86696 | <1% | 16 | $212.85 | |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | <1% | 138 | $197.80 |
| 82105 | <1% | 18 | $184.47 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 308 | $179.37 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 93 | $170.29 |
| 86300 | <1% | 13 | $166.48 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 66 | $164.45 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 81 | $161.72 |
| 82947 | <1% | 48 | $156.85 | |
| 81050 | <1% | 38 | $150.81 | |
| 86695 | <1% | 15 | $131.90 | |
| 84153 | <1% | 12 | $128.73 | |
| 83050 | <1% | 26 | $125.73 | |
| 86708 | <1% | 17 | $123.90 | |
| 85045 | <1% | 29 | $104.76 | |
| J2598 | Injection, vasopressin, 1 unit | <1% | 69 | $104.41 |
| 80076 | <1% | 12 | $99.94 | |
| 80164 | <1% | 15 | $94.78 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 89 | $94.28 |
| 85007 | <1% | 40 | $91.96 | |
| 84460 | <1% | 18 | $89.93 | |
| 84450 | <1% | 18 | $87.90 | |
| 84165 | <1% | 12 | $85.92 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 18 | $70.84 |
| 81002 | <1% | 14 | $41.81 | |
| 85014 | <1% | 19 | $32.31 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 99 | $29.73 |
| J1250 | Injection, dobutamine hydrochloride, per 250 mg | <1% | 15 | $24.18 |
| 99499 | <1% | 64 | $9.63 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCARRICO, RICHARD (CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.